Research And Drug Development Consultant
Vumab Ag
AeroLeads people directory · profile
Minh Diem Vu Email & Phone Number
Research and Drug Development Consultant
at
vumab AG
LinkedIn matched
✓ Verified July 2026
3 data sources
Profile completeness 100%
Current company
vumab AG
Role
Research and Drug Development Consultant
Location
Zurich, Switzerland
Who is Minh Diem Vu? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
Minh Diem Vu is listed as Research and Drug Development Consultant at vumab AG, based in Zurich, Switzerland. AeroLeads shows a matched LinkedIn profile for Minh Diem Vu.
Minh Diem Vu previously worked as Research & Drug Development Consultant at Vumab Ag and Executive Research at Celgene Engmab Gmbh, A Bristol-Myers Squibb Company. Minh Diem Vu holds Doctor Of Philosophy (Ph.D.), Biomedical Sciences (Transplantation Immunology) from Université De Montréal.
Profile bio
About Minh Diem Vu
Minh Diem Vu, Ph.D. is a highly engaged and passionate scientist with broad range R&D experience in small biotechnologies and pharmaceutical industry, committed to find better therapies for patients with unmet medical needs. In 2013, she co-founded EngMab AG, a Swiss start-up biotechnology company focused on cancer immunotherapy (T cell bispecific antibodies). As the preclinical research expert, member of the core operational team and board of directors of EngMab, she was centrally involved in activities related to science, R&D and operation leading to the sale of EngMab in 2016. As a trained biologist and immunologist, Dr. Vu holds a Ph.D. in Biomedical Sciences from Université de Montréal (Quebec, Canada) and completed a 3-year postdoctoral fellowship in Transplant Immunology at Beth Israel Deaconess Medical Center affiliated to Harvard University (Boston, MA, USA). Before co-founding EngMab, Dr. Vu worked at Roche where she gained relevant expertise in drug R&D. She first joined the Inflammation Discovery group at Roche Palo Alto, LLC (CA, USA) and further expanded her experience at Hoffman-La Roche (Nutley, NJ, USA). As a research Laboratory Head with managerial role, she led early-stage portfolio projects and was heavily involved in the development of antibody-based therapies and small molecule immunomodulatory drug candidates. Dr. Vu has authored more than 35 publications including scientific papers in high impact peer-reviewed journals, granted patents and patent applications. Specialties: Immunology, Hematological Malignancies, Transplantation, Inflammation, Autoimmunity, Biology, R&D, Preclinical, Basic, Translational science, Academic Collaborations, Fundraising, Due-Diligence, Scientific Papers, Patents, Project Leadership, Immunology, Cellular and Molecular Techniques, Mechanistic and Functional PD Assays, Biomarkers, Managerial Responsibilities, Cancer Immunotherapy, Engineered Antibodies, Small Molecules, Kinase Inhibitors, Antimetabolites.
Listed skills include Research, In Vivo, and Inflammation.
Current workplace
Minh Diem Vu's current company
Company context helps verify the profile and gives searchers a useful next step.
Vumab Ag
9 roles
Minh Diem Vu work experience
A career timeline built from the work history available for this profile.
Research & Drug Development Consultant
Vumab Ag
Executive Research
Celgene Engmab Gmbh, A Bristol-Myers Squibb Company
Nov 2019 - Aug 2021
Executive Research
Celgene Engmab Gmbh, A Celgene Company
Oct 2016 - Nov 2019
Preclinical Research, Board Member, Co-Founder
Engmab Ag
- Preclinical Research, R&D- Immunology, Hematological Malignancies- Operational Core Team: Budget, Fundraising, Deliverable and Milestones- Academic Collaborations, Interactions with CROs/CMOs and Legal and Scientific Consultants- Patent Applications- Start-up Company Foundation (since inception/Newco)- Key Involvement in activities related to Science, R&D and Operation leading to the sale of EngMab AG
Sep 2013 - Oct 2016
Research Scientist Ii (Inflammation Discovery, In Vivo And Translational Biology)
Jun 2009 - Apr 2011
Research Scientist Ii (Inflammation Discovery, In Vivo Pharmacology)
Mar 2009 - Jun 2009
Research Scientist I (Inflammation Discovery, Transplantation Research)
Jul 2006 - Mar 2009
Postdoctoral Fellow
1) Vu MD, Amanullah F, Demirci G, Li Y, Strom TB, Yagita H, Sayegh MH, Li XC. Different costimulatory and growth factor requirements for CD4+ and CD8+ mediated rejection. J Immunol 2004; 173 (1): 214-21.2) Vu MD, Li XC. Study of T cell costimulatory blockade in vivo at a single cell level. Adoptive Immunotherapy: Methods and Protocols. Methods in Molecular Medicine Series 2004; 109 (27): 409-20 (chapter).3) Vu MD, Li XC. The common gammac-cytokines and transplantation tolerance. Arch Immunol Ther Exp (Warsz) 2004; 52 ( 4): 267-73 (review).4) Vu MD, Li Y, Strom TB, Li XC. Mycophenolate mofetil is compatible with CD28/CD154 costimulatory blockade in preventing transplant rejection. Transplantation 2005; 79 (8): 736 (Letter to Editor).5) Vu MD, Clarkson MR, Yagita H, Turka LA, Sayegh MH, Li XC. Critical, but conditional, role of OX40 in memory T cell-mediated rejection. J Immunol 2006; 176 (3): 1394-401.6) Yu G, Xu X, Vu MD, Kilpatrick ED, Li XC. NK cells promote transplant tolerance by killing donor antigen-presenting cells. J Exp Med 2006; 203 (8): 1851-8.7) Vu MD, X Xiao, W Gao, N Degauque, M Chen, A Kroemer, N Killeen, N Ishii, XC Li. OX40 costimulation turns off Foxp3+ TREGS. Blood 2007; 110 (7): 2501-10.8) Kroemer A, Xiao X, Vu MD, Gao W, Minamimura K, Chen M, Maki T, Li XC. OX40 controls functionally different T cell subsets and their resistance to depletion therapy. J Immunol. 2007; 179 (8): 5584-91.9) Habicht A, Kewalaramani R, Vu MD, Demirci G, Blazar BR, Sayegh MH, Li XC. Striking dichotomy of PD-L1 and PD-L2 pathways in regulating alloreactive CD4(+) and CD8(+) T cells in vivo. Am J Transplant. 2007; 7 (12): 2683-92.10) Degauque N, Mariat C, Kenny J, Zhang D, Gao W, Vu MD, Alexopoulos S, Oukka M, Umetsu DT, Dekruyff RH, Kuchroo V, Zheng XX, Strom TB. Immunostimulatory Tim-1-specific antibody deprograms Tregs and prevents transplant tolerance in mice. J Clin Invest. 2008; 118 (2): 735-41.
May 2003 - Jul 2006
3 education records
Minh Diem Vu education
Doctor Of Philosophy (Ph.D.), Biomedical Sciences (Transplantation Immunology)
Master Of Science (M.Sc.), Biomedical Sciences (Transplantation Immunology)
Bachelor Of Science (B.Sc.), Biomedical Sciences
FAQ
Frequently asked questions about Minh Diem Vu
Quick answers generated from the profile data available on this page.
What company does Minh Diem Vu work for?
Minh Diem Vu works for vumab AG.
What is Minh Diem Vu's role at vumab AG?
Minh Diem Vu is listed as Research and Drug Development Consultant at vumab AG.
Where is Minh Diem Vu based?
Minh Diem Vu is based in Zurich, Switzerland while working with vumab AG.
What companies has Minh Diem Vu worked for?
Minh Diem Vu has worked for Vumab Ag, Celgene Engmab Gmbh, A Bristol-Myers Squibb Company, Celgene Engmab Gmbh, A Celgene Company, Engmab Ag, and Hoffmann-La Roche.
How can I contact Minh Diem Vu?
You can use AeroLeads to view verified contact signals for Minh Diem Vu at vumab AG, including work email, phone, and LinkedIn data when available.
What schools did Minh Diem Vu attend?
Minh Diem Vu holds Doctor Of Philosophy (Ph.D.), Biomedical Sciences (Transplantation Immunology) from Université De Montréal.
What skills is Minh Diem Vu known for?
Minh Diem Vu is listed with skills including Research, In Vivo, and Inflammation.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trialPeople with similar names
Check these profiles if this is not the Minh Diem Vu you were looking for.
View similar profiles
